NCT06841770 A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury
| NCT ID | NCT06841770 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Lineage Cell Therapeutics, Inc. |
| Condition | Spinal Cord Injury Cervical |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2025-06-30 |
| Primary Completion | 2027-08-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 10 participants in total. It began in 2025-06-30 with a primary completion date of 2027-08-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The DOSED clinical study evaluates the safety and utility of a novel delivery device to deliver LCTOPC1, a cell therapy, to the spinal cord of patients with a spinal cord injury (SCI). LCTOPC1 is designed to replace or support cells that are absent or dysfunctional due to traumatic injury, with a goal to help improve the quality of life and restore or augment functional activity in persons suffering from a traumatic cervical or thoracic injuries.
Eligibility Criteria
Inclusion Criteria: 1. Sensorimotor complete, traumatic SCI (ASIA Impairment Scale A) or sensory incomplete, traumatic SCI (ASIA Impairment Scale B) 2. For subjects with subacute injury, International Standards for Neurological Classification of SCI (ISNCSCI) Neurological Level of Injury (NLI) from C-4 to T-10 occurring 21 to 42 days prior to LCTOPC1 injection 3. For subjects with chronic injury, ISNCSCI NLI from C-4 to T-10 and more than 30 days without clinical improvement from last assessment, occurring 1 to 5 years prior to LCTOPC1 injection 4. Individuals must have at least one upper extremity ISNCSCI key muscle with at least 1/5 strength 5. 18 through 65 years of age, inclusive, at time of consent 6. Single injury with sufficient visualization of the spinal cord injury epicenter and lesion margins to enable post-injection safety monitoring 7. Informed consent for this protocol must be provided and documented (i.e., signed ICF) 8. Able to participate in an elective surgical procedure to inject LCTOPC1 21 days or later following SCI 9. Female subjects of child-bearing potential must agree to the use of contraception for 1 year following LCTOPC1 injection; male subjects must agree to use contraception to prevent pregnancy in any female partners of child-bearing potential for 1 year following LCTOPC1 injection Exclusion Criteria: 1. SCI due to penetrating trauma 2. Traumatic anatomical transection, laceration, or inadequate decompression of the spinal cord based on prior surgery or MRI 3. Any concomitant injury that interferes with the performance, interpretation, or validity of neurological examinations, such as multiple spinal cord lesions, brachial/lumbar plexus injury, cauda equina injury or traumatic brain injury 4. Subjects with a cavity structure that would preclude successful transplantation, as identified on MRI, which may include septations or irregularities in tissue structure 5. Persons with syringomyelia, defined as those with progressively enlarging cysts on T2-weighted images associated with neurological decline 6. Inability to communicate effectively with neurological examiner such that the validity of patient data could be compromised 7. Organ damage or systemic disease that would create an unacceptable risk for surgery or immunosuppression 8. Need for mechanical support of ventilation (ventilator, continuous positive airway pressure \[CPAP\], bi-level positive airway pressure \[BiPAP\]), excluding supplemental oxygen, at baseline 9. History of any malignancy (except non-melanoma skin cancers). For cancers in remission for more than five years, enrollment is allowed with concurred documented approval of principal investigator, oncologist, and Sponsor's medical monitor prior to enrollment 10. Pregnant or nursing women 11. Subjects with an implanted spinal cord stimulator (SCS), whether temporary or permanent.
Contact & Investigator
Reference Study ID Number: LCTOPC1-SCI-03 https://lineagecell.com/products-pipeline/opc1/
✉ ClinicalTrials@lineagecell.com📞 442-287-8940
Frequently Asked Questions
Who can join the NCT06841770 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Spinal Cord Injury Cervical. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06841770 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06841770 currently recruiting?
Yes, NCT06841770 is actively recruiting participants. Contact the research team at ClinicalTrials@lineagecell.com for enrollment information.
Where is the NCT06841770 trial being conducted?
This trial is being conducted at Downey, United States, La Jolla, United States.
Who is sponsoring the NCT06841770 clinical trial?
NCT06841770 is sponsored by Lineage Cell Therapeutics, Inc.. The trial plans to enroll 10 participants.